NCT05488626

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

Daily Adaptive vs Non-Adaptive External Beam Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Trial of an Individualized Approach for Toxicity Reduction (ARTIA-Lung)

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Varian, a Siemens Healthineers Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased acute respiratory and esophageal toxicity compared with non-adaptive radiotherapy with concomitant chemotherapy. The timepoint for this assessment will be 3 months following the end of radiotherapy and will use the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Conditions

• Stage III Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DEVICE	Adaptive Radiotherapy	Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.
DEVICE	Non-Adaptive Radiotherapy	Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.
DRUG	Chemotherapy	Concomitant chemotherapy per NCCN or other national guidelines.
DRUG	Immunotherapy	Adjuvant immunotherapy per national or institutional guidelines.

Timeline

• Start date: 2022-10-20
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2022-08-04
• Last updated: 2026-02-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study